-
Mashup Score: 0Guiju Sun Bio | American Association for Cancer Research - 2 year(s) ago
Q: What is your primary area of study/research? A: Nutrition and chronic disease (including cancer); the effects of different fatty acids on human health; phytochemicals; food efficacy; cancer epidemiology; nutritional epidemiology. Q: What influenced your decision to embark on a research career? A: My interest in scientific research drives me to embark on a research career. I hope to…
Source: aacrjournals.orgCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 4Abatacept Shows Signal to Delay Onset of Rheumatoid Arthritis - 3 year(s) ago
Early results of a randomized clinical trial show that a 6-month course of abatacept may delay or prevent progression to rheumatoid arthritis.
Source: MedscapeCategories: General Medicine News, Latest HeadlinesTweet-
Early results of a randomized clinical trial show that a 6-month course of abatacept may delay or prevent progression to #RheumatoidArthritis. https://t.co/McqQ6GSOG5 #AACR21 https://t.co/7rSo3DVI64
-
-
Mashup Score: 12Rituximab Improves Systemic Sclerosis Skin, Lung Symptoms - 3 year(s) ago
Patients who took rituximab in the DESIRES trial had better skin scores and lung function at 6 months than did patients who received placebo.
Source: MedscapeCategories: General Medicine News, Latest HeadlinesTweet-
Rituximab effectively reduced skin sclerosis and appeared to have a beneficial effect on ILD for patients with SSc in a randomized, clinical trial. #AACR21 https://t.co/OfrKepKbuc https://t.co/juJRrx71zZ
-
-
Mashup Score: 0
Proceedings: AACR Annual Meeting 2021; April 10-15, 2021 and May 17-21, 2021; Philadelphia, PA Background: National Comprehensive Cancer Network guidelines have recommended metastatic colorectal cancer patients (mCRC pts) undergo BRAF, KRAS, NRAS, and microsatellite instability/mismatch repair deficiency (MSI/MMR) testing since 2015. Previous studies have reported molecular testing rates from…
Source: Cancer ResearchCategories: Hem/Oncs, Latest HeadlinesTweet-
Staged analysis of standard of care tumor molecular testing among patients with metastatic colorectal cancer in the community health system setting [Jul 2021] Zhang et al. @TDBrownMD Abstract 2618 #AACR21 https://t.co/mKe1Yfs13m #PrecisionMedicine #crcsm #camets https://t.co/IhO4e3s5vF
-
-
Mashup Score: 0RP-3500 Shows Promising Safety, Clinical Activity in Solid Tumors With Synthetic Lethal Genomic Alterations - 3 year(s) ago
The ATR inhibitor RP-3500 demonstrated a manageable safety profile and promising early antitumor efficacy in patients whose tumors harbor select genomic alterations when administered at doses of 100 mg or more.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
The ATR inhibitor RP-3500 demonstrated a manageable safety profile and promising early antitumor efficacy in patients whose tumors harbor select genomic alterations when administered at doses of 100 mg or more. @MDAndersonNews @AACR #AACR21 #oncology https://t.co/oZANoXUnuq
-
-
Mashup Score: 1RP-3500 Shows Promising Safety, Clinical Activity in Solid Tumors With Synthetic Lethal Genomic Alterations - 3 year(s) ago
The ATR inhibitor RP-3500 demonstrated a manageable safety profile and promising early antitumor efficacy in patients whose tumors harbor select genomic alterations when administered at doses of 100 mg or more.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Results from the phase 1/2 TRESR study showed that meaningful clinical benefit was observed in 49% of 69 patients, with 12 patients experiencing objective tumor responses. @MDAndersonNews @AACR #AACR21 #oncology https://t.co/V8H8sj3cEz https://t.co/Otag0S8RYf
-
-
Mashup Score: 3RP-3500 Shows Promising Safety, Clinical Activity in Solid Tumors With Synthetic Lethal Genomic Alterations - 3 year(s) ago
The ATR inhibitor RP-3500 demonstrated a manageable safety profile and promising early antitumor efficacy in patients whose tumors harbor select genomic alterations when administered at doses of 100 mg or more.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
RP-3500 Shows Promising Safety, Clinical Activity in Solid Tumors With Synthetic Lethal Genomic Alterations @MDAndersonNews @AACR #AACR21 #oncology https://t.co/w1pvC4f0aM
-
-
Mashup Score: 3Racial and Ethnic Diversity in Clinical Trials Evaluating Hematologic Malignancies — AACR Annual Meeting 2021 - 3 year(s) ago
Friday, May 21, 2021: Ashley Woods and Bindu Kanapuru of the U.S. Food and Drug Administration (FDA) moderated this panel discussion at the AACR Annual Meeting 2021.
Source: VimeoCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Racial and Ethnic Diversity in Clinical Trials Evaluating Hematologic Malignancies: Ashley Woods @acw_md and Bindu Kanapuru @FDAOncology moderated a panel discussion on this topic during a Science Policy session at #AACR21. Watch the session: https://t.co/ALgcMto99g https://t.co/PNdWpd6Esx
-
-
Mashup Score: 0
Proceedings: AACR Annual Meeting 2021; April 10-15, 2021 and May 17-21, 2021; Philadelphia, PA Background: National Comprehensive Cancer Network guidelines have recommended metastatic colorectal cancer patients (mCRC pts) undergo BRAF, KRAS, NRAS, and microsatellite instability/mismatch repair deficiency (MSI/MMR) testing since 2015. Previous studies have reported molecular testing rates from…
Source: Cancer ResearchCategories: Hem/Oncs, Latest HeadlinesTweet-
Staged analysis of standard of care tumor molecular testing among patients with metastatic colorectal cancer in the community health system setting [Jul 2021] Zhang et al. @TDBrownMD Abstract 2618 #AACR21 https://t.co/mKe1Yfs13m #PrecisionMedicine #crcsm #camets https://t.co/e8OKSSjQly
-
-
Mashup Score: 3FDA OCE Engagement Efforts: Building an Inclusive Cancer Community — AACR Annual Meeting 2021 - 3 year(s) ago
Monday, May 17, 2021: Paul G. Kluetz and Rea Blakey of the U.S. Food and Drug Administration moderated this panel discussion at the AACR Annual Meeting 2021.
Source: VimeoCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
A critical step in achieving the goal of health equity is the development of an inclusive cancer community. At #AACR21, @rea_blakey and @pkluetz of @FDAOncology moderated a panel to discuss the agency's efforts to reach underserved populations. Watch now: https://t.co/gzJF47SXyf https://t.co/zRkhzyS1ei
-
If you haven't you read the Best of Author Profile featuring a Q&A with CAPR author Guiju Sun, then check it out now: https://t.co/Y3liq6nLXC. #AACR21 https://t.co/IfLTNtjo3f